Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Decidua Stromal Cells vs Best Available Treatment in Steroid-Refractory Acute GvHD
2024-511768-97-01Phase 2Completed
- Sponsor
- Oslo University Hospital
- Start
- Nov 2024
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 3
01
Overview
Phase 2, randomised, open-label trial of decidua stromal cells in Acute Graft-Versus-Host Disease (aGvHD) (2 arms), sponsored by Oslo University Hospital. Primary endpoints: Safety (AEs and SAEs related to DSC) and Durable overall response rate at Day 56. Started Nov 2024; status: completed.
02
Drugs
decidua stromal cells
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on 2024-511768-97-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511768-97-01.